Thrombi in control and RBC HIGH mice did not differ in size or fibrin content, and there was no difference in levels of circulating thrombin-antithrombin complexes. In vitro, increasing the hematocrit increased thrombin generation in the absence of platelets; however, this effect was reduced in the presence of platelets. In silico, direct numerical simulations of whole blood predicted elevated hematocrit increases the frequency and duration of interactions between platelets and a thrombus. When human whole blood was perfused over collagen at arterial shear rates, elevating the hematocrit increased the rate of platelet deposition and thrombus growth. These data suggest RBCs promote arterial thrombosis by enhancing platelet accumulation at the site of vessel injury. Maintaining a normal hematocrit may reduce arterial thrombosis risk in humans.
INTRODUCTION
Red blood cells (RBCs) are the most abundant cells in blood. Normal RBC numbers range from 4.2-to-6.1×10 9 /mL in humans; males have slightly higher levels than females. RBCs are primarily known for their hemoglobin-mediated role in oxygen transport. However, a growing body of evidence suggests RBCs have biochemical and biophysical properties that may contribute to thrombosis. First, RBCs are the principal determinant of blood viscosity, an established risk factor for thrombosis. 1 Blood viscosity increases non-linearly with increased hematocrit. 2, 3 Consequently, elevated hematocrit, even within a clinically-relevant range (40-60%), increases blood viscosity at both arterial and venous shear rates. 4 Second, simulations and experimental studies using models of intact (uninjured) arteries suggest RBCs enrich the near-wall region with platelets (margination). 5, 6 Third, RBCs enhance platelet α IIb β 3 activation and P-selectin exposure in response to agonists (e.g., collagen, thrombin). [7] [8] [9] Fourth, platelet accumulation on excised subendothelial matrices increases with increasing hematocrit (10-70%) at arterial shear rates. 10 Finally, RBCs and RBC-derived microvesicles have exposed phosphatidylserine on their outer membrane and can support thrombin generation in vitro. [11] [12] [13] [14] [15] [16] [17] [18] Overall, these studies support the hypothesis that elevated RBCs can directly enhance thrombosis. However, which, if any, of these pathways contribute to thrombosis in vivo is unclear. Determining the contribution of RBCs to coagulation in vivo is clinically important because elevated hematocrit is an independent risk factor for cardiovascular disease and cardiovascular-related deaths. [19] [20] [21] [22] [23] [24] Thus, increased understanding of the relationship between hematocrit and thrombosis is needed to guide clinical strategies.
Previous studies in animal models have examined the pathophysiologic effects of elevated hematocrit in JAK 2
V617F
-induced polycythemia vera (PV) or erythrocytosis mediated by endogenous overproduction of erythropoietin. [25] [26] [27] [28] Findings from these studies expose complex, and sometimes discordant, effects of hematocrit on coagulation and failed to reveal a clear relationship between hematocrit and thrombosis. For example, a mouse model of JAK 2
-induced PV exhibits a prothrombotic phenotype following FeCl 3 injury to mesenteric vessels, but an apparent paradoxical increase in bleeding following tail transection. 27 However, these mice are deficient in platelet GPVI and have reduced plasma von Willebrand factor multimers 27 , making it difficult to assess the contribution of elevated hematocrit to thrombosis. Mice genetically-engineered to overexpress human erythropoietin also show increased bleeding in a tail bleeding model. 26 However, these animals have a markedly increased hematocrit (80-85%) not seen in humans, and the increased bleeding may be explained by a Dallas, TX) and the hematocrit adjusted to 70%. Recipient 6-to-8-week old male C57Bl/6 mice were anesthetized, injected with packed RBCs via retro-orbital plexus (~250 µL), and allowed to recover.
After 24 hours, blood was drawn from the inferior vena cava for hematological analysis or animals were subjected to thrombosis models (separate mice). Methods for blood smears, flow cytometry, thrombinantithrombin complex (TATc), and whole blood viscosity measurements are detailed in Supplemental Materials.
Mouse models of clotting. The FeCl 3 injury model was performed as described. 33, 34 Briefly, 6-to-8-week old male C57Bl/6 mice were anesthetized. The right common carotid artery was exposed, dried, and treated with FeCl 3 (10%, 0.5x0.5-mm filter paper, 2 min). Blood flow was monitored auditorily by following the thrombus onset time). Mice that did not experience carotid occlusion were omitted from onset and rate analysis because they did not form defined thrombi.
Tail transection assays were performed as described in Supplemental Materials. Thrombin generation in reconstituted human whole blood. Thrombin generation was measured using whole blood calibrated automated thrombography 15 as detailed in Supplemental Materials.
Computational modeling. Simulations of human whole blood flow driven by a pressure gradient through a 50-µm channel were conducted with a custom Lattice-Boltzmann Immersed Boundary method code. [35] [36] [37] For each simulation, the channel was partially occluded by a preformed thrombus of specified shape and size. The pressure gradient was set to achieve a wall shear rate of approximately 1100 sec
At a sequence of times, the fluid velocity field was computed, accounting for mechanical forces generated by numerous deformable RBCs and a smaller number of less deformable platelets. 
RESULTS

Experimental model of elevated hematocrit in mice. To study the effect of elevated hematocrit in vivo,
we used an experimental model in which we raised the hematocrit in healthy mice with fresh, washed RBCs from healthy donor mice. Complete blood counts showed RBC HIGH mice had an elevated hematocrit compared to control mice (P<0.0001, Figure 1A , Table I ). Levels of neutrophils and monocytes were similar in controls and RBC HIGH mice ( Figure 1B -C, Table I ). Platelet levels were slightly lower in RBC HIGH mice compared to controls ( Figure 1D , Table I Figure 2B ), but the thrombus formation rate was significantly faster (0.020±0.006 versus 0.012±0.003 min -1 , respectively, mean±SD, P<0.05, Figure 2C ).
To test whether elevated hematocrit promoted clotting in a second in vivo model, we subjected control and RBC HIGH mice to a tail transection assay. Elevated hematocrit did not shorten the clotting time under normal conditions, likely due to the already very short clotting time (median ~88 sec).
However, when mice were infused with heparin to prolong the clotting time, RBC HIGH mice had a shorter clotting time than control mice (P<0.05, Figure 2D ). Together, data from these two models suggest elevated hematocrit accelerates clot formation in vivo.
Thrombi from control and RBC HIGH mice do not differ in size or fibrin content. To determine how elevated hematocrit accelerates thrombosis, we first excised the occluded carotid artery from a subset of mice subjected to FeCl 3 injury. Both control and RBC HIGH mice had fully occlusive thrombi that were similar in size ( Figure 3A ,B). Thrombi from both control and RBC HIGH mice were primarily composed of proteinaceous material with sparse, small islands of RBCs, and showed similar fibrin staining (amount and intensity, Figure 3A ). These data suggest elevated hematocrit does not increase thrombus size or fibrin content.
Thrombin generation does not differ in control and RBC HIGH mice in vivo.
We then tested the hypothesis that RBC HIGH mice had enhanced activation of coagulation following FeCl 3 injury. We drew blood from mice 5 min after artery occlusion and measured TATc in plasma. TATc were similar in control and RBC HIGH mice (7.1±2.8 and 9.8±5.3 ng/mL, respectively, mean±SD, P=0.32, Figure 3C ), and circulating TATc levels did not correlate with hematocrit ( Figure 3D ). These data suggest elevated levels of normal RBCs do not promote thrombus formation by increasing thrombin generation. Figure 4 . We then triggered coagulation with tissue factor and recalcification and measured thrombin generation by whole blood calibrated automated thrombography. In the absence of platelets, increasing hematocrit increased the thrombin generation rate, peak, and endogenous thrombin potential ( Figure 4 , Table II ). This finding is consistent with prior studies 12, 13, 15 , and is thought to reflect prothrombin cleavage on the surface of phosphatidylserine-expressing RBCs. 12 However, in reactions with 200x10 6 platelets/mL, hematocrit had less effect on thrombin generation (Figure 4 , Table II) , and in reactions with 450x10 6 platelets/mL, there was no effect of hematocrit on thrombin generation ( Figure 4 , Table II platelets resulting from simulations at 40 and 60% hematocrit. These data reveal a zone along a straight wall in which RBC concentrations were reduced and platelet concentrations were enhanced, and that this near-wall zone was narrower for 60% than 40% hematocrit ( Figure 5A,B) . The zone's width was also smaller for 60% than 40% hematocrit both upstream of (1.0 versus 3.0 µm, respectively) and over (0.28 versus 1.28 µm, respectively) a small thrombus ( Figures 5C,D) . Results were similar in simulations with larger thrombi (data not shown). This decreased near-wall zone resulted from increased interstitial velocity within the porous thrombus versus the solid wall. Narrowing of this zone pushed platelets close to the thrombi, so that platelets spent more time in proximity to the thrombus than to a comparable segment of flat vessel wall; i.e., at 40% hematocrit, for the same trajectory length (44 µm), platelets spent 11.5 msec within 0.5 µm of the porous thrombus versus only 3.1 msec near the solid wall. For personal use only. on April 5, 2017. by guest www.bloodjournal.org From (29.5±26.6 msec versus 11.5±10.0 msec, respectively, mean±SD). Trends for the larger thrombus were similar, but interactions were even longer and showed a greater difference between hematocrits (41.0±39.4 versus 15.4±9.5 msec, mean±SD). Consistent with previous studies 37 , interactions in both cases were particularly frequent and prolonged near the upstream face of the thrombus. A linear fit of mean platelet interaction times with the small thrombus for 40% and 60% hematocrits predicts an increase of ~55% in the mean interaction time for a 47% hematocrit. The analogous calculation for the large thrombus predicts an increase of 58%. These predicted values from the simulations agree well with the 67% increase in mean thrombus growth rate observed in vivo for 47% versus 40% hematocrit.
Effect of RBCs
Together, these data suggest elevated hematocrit enhances platelet contact with a thrombus in flowing blood, and that the frequency of these interactions increases with thrombus growth. ). Consistent with the in vivo findings and predictions from in silico simulations, elevated hematocrit significantly accelerated thrombus growth ( Figure 6A,B) , exposing a direct, prothrombotic effect of increased hematocrit on thrombus formation. The sensitivity of these in vitro experiments to very early thrombus formation also revealed a small, but significant, shortening of the lag time to thrombus initiation that was not detectable in the in vivo experiments. This reduction in lag time is consistent with in silico predictions of enhanced margination at higher hematocrit near a straight, non-porous wall ( Figure 5A ,B). There was no measurable effect of hematocrit on fibrin deposition (data not shown), consistent with in vivo and in vitro findings indicating little-to-no effect of elevated hematocrit on thrombin generation or fibrin formation at normal platelet counts.
Notably, however, Figure 6C illustrates a moderate, though significant, effect of hematocrit on the rate of platelet accumulation in the thrombus. This finding is consistent with predictions from the computational model suggesting elevated hematocrit increases the frequency and duration of plateletthrombus interactions, and therefore, the likelihood that these interactions will result in platelet accumulation in the thrombus. Collectively, these data suggest elevated hematocrit promotes platelet interactions with a forming thrombus, leading to faster platelet accumulation and accelerated thrombus growth. Epidemiologic studies of healthy humans associate elevated hematocrit with thrombosis, and suggest increased risk exists at even moderately-elevated baseline hemoglobin/hematocrit levels. In a large prospective cohort analysis (>8,000 subjects), incidence of myocardial infarction (MI), coronary insufficiency, or coronary heart disease deaths was more than double in individuals with high hematocrit (>49%) compared to individuals with low hematocrit (<42%). 19 Likewise, the Framingham study followed >5,000 men and women (30-62 years old) over 34 years and showed that compared to individuals in the mid-hematocrit quintile, young men and women in the highest quintile (men ≥ 49%, women ≥ 46%) had an increased risk of death from cardiovascular disease. 21 Similarly, in the British Regional Heart Study involving >7,700 men, risk of major ischemic heart disease events was increased by 30% at hematocrit >46%, compared to those below this cut-off. 22 Additional longitudinal studies of young men showed that a high hematocrit at baseline was associated with 1.4-to-1.9-fold increased risk of MI during the follow-up period. 20, 24 In most of these studies, the association with thrombosis was independent of other cardiovascular risk factors, including smoking, itself a recognized cause of elevated hematocrit.
Increased hematocrit has also been implicated in thrombosis associated with a number of erythrocytotic disorders including PV, Chuvash polycythemia, and erythropoietin-induced erythrocytosis. In PV, risk of cardiovascular death and major thrombosis is significantly reduced by maintaining the hematocrit <45%, compared to 45-50%. 42 However, determining specific prothrombotic effects of hematocrit in these patients is complicated by the underlying disease pathophysiology.
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Together with older studies, our findings provide biophysical mechanisms that may explain these observations: elevated hematocrit increases the duration and frequency of platelet-thrombus interactions.
In contrast to most computational studies of margination in long, straight tubes 35, [43] [44] [45] [46] , our model includes the perturbation of blood flow by a thrombus penetrating into the lumen. Importantly, like thrombi in vivo 47 , the thrombi in our in silico model are porous, allowing for interstitial flow through the thrombus interior. The magnitude of interstitial flow increases with hematocrit, ultimately pushing platelets closer to the surface, while reducing tumbling. As a result, platelets are in close proximity to the thrombus for longer times, increasing the probability of receptor-ligand bond formation. Related in silico studies show that even at a hematocrit of 10%, RBCs enhance platelet deposition in stenosed vessels, in part by reducing the distance between a platelet and a non-porous thrombus. 48 Effects of elevated hematocrit on platelet accumulation in our assays were significant but moderate, consistent with the moderately increased risk observed in epidemiologic studies. [19] [20] [21] 24 Notably, the premise that elevated hematocrit promotes thrombosis via platelet-dependent mechanisms is consistent with clinical findings that platelet antagonism reduces cardiovascular death, non-fatal MI, and stroke in patients with PV. 49 Thus, these data may provide rationale for the efficacy of platelet inhibition strategies in patients with elevated hematocrit and increased thrombosis risk.
Since RBCs can support thrombin generation [12] [13] [14] [15] , the observation that elevated hematocrit did not increase circulating TATc was somewhat surprising. However, the dependence of arterial thrombosis on platelet function 50 and scarcity of RBCs in the thrombus ( Figure 3A For personal use only. on April 5, 2017 . by guest www.bloodjournal.org From prothrombotic effects of elevated hematocrit in both murine and human experimental systems. Second, although FeCl 3 is a common agent for inducing thrombosis in animal models, ferric ions cause chargesuppression of plasma proteins and blood cells leading to initial adhesion of blood cells, including RBCs, to the endothelium by non-biological mechanisms. [56] [57] [58] [59] [60] However, subsequent propagation of thrombus into the vessel lumen, including platelet accumulation and thrombus growth, is still thought to recapitulate key aspects of arterial thrombus formation. 57, 60 Moreover, results were supported by independent experimental systems in vivo (tail transection), in silico (simulation), and in vitro (microfluidics). Third, our findings are limited to mildly elevated hematocrit. In future studies, it may be useful to examine the relationship between hematocrit and thrombosis across a broader range. Such studies may identify a non-linear, and even J-shaped 21 , response to hematocrit. For example, in situations where hematocrit elevation is extreme such as in patients with cyanotic congenital heart disease, hyperviscosity may paradoxically manifest as a bleeding tendency 61 , an association that can also be seen in mice with extremely high hematocrits 26 . Thus, the relationship between thrombosis and elevated hematocrit/hemoglobin may be complex and dependent on the mechanism and degree of erythrocytosis. Finally, our study does not address potential effects of chronically-elevated hematocrit, in which additional systemic effects may also impact thrombosis.
In summary, our data suggest elevated hematocrit promotes arterial thrombosis. Effects are independent of thrombin generation, but associated with accelerated platelet accumulation within the thrombus. These findings suggest maintaining a normal hematocrit or reducing platelet function in patients with elevated hematocrit may reduce arterial thrombosis risk. 
